HEADLINE ALTERATION

The headline for the Physiomics plc announcement released on 15 October 2024 at 11:30am under RNS No 2609I should read IMC Presentation on Company Website.

The announcement text is unchanged and is reproduced in full below.

15 October 2024

Physiomics plc

("Physiomics" or the "Company")

IMC Presentation on Company Website

Physiomics plc (AIM: PYC), a leading mathematical modelling, data science and biostatistics company supporting the development of new therapeutics and personalised medicine solutions, recently provided a brief update in-line with its End of Year results via Investor Meet Company and has updated its website with the presentation.

The presentation and Q&A from the meeting are now available at the Company's website:

https://www.physiomics.co.uk/portfolio-item/investor-presentation-full-year-results-and-company-update/

Enquiries:

Physiomics plc

Dr Jim Millen, Non-Executive Chairman

Dr Peter Sargent, Chief Executive Officer

+44 (0)1235 841575

Hybridan LLP (Broker)

Claire Louise Noyce

+44 (0) 203 764 2341

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

Notes to Editor

About Physiomics

Physiomics plc combines expertise across Modelling & Simulation, Biostatistics, Data Science and Bioinformatics, together with deep biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to help derive insight from all relevant and often disparate data in order to de-risk decision making and optimise research design across discovery, pre-clinical and clinical studies. Through use of cutting-edge computational tools, bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, with over 125 targets and drugs modelled. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.